8-K: Sonendo Announces Preliminary Q3 2024 Results and Raises Full-Year Revenue Guidance

Sonendo reports preliminary Q3 2024 revenue between $7.9 and $8.0 million and increases its full-year 2024 revenue guidance.

Summary

• Sonendo has released preliminary unaudited financial results for the third quarter of 2024, ending September 30th.
• Total revenue is expected to be between $7.9 million and $8.0 million.
• Console revenue is estimated at approximately $1.8 million, while procedural instrument revenue is expected to be around $5.1 million.
• The company has maintained a double-digit console backlog for the third consecutive quarter.
• Cash, cash equivalents, and short-term investments are projected to be approximately $17.3 million as of September 30, 2024.
• Sonendo is increasing its full-year 2024 revenue guidance to a range of $31.5 million to $32.5 million, up from the previous range of $31.0 million to $32.0 million.
• The company is also pursuing the acquisition of certain assets of Biolase, Inc. through a stalking horse bid in their Chapter 11 bankruptcy proceedings.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the increased revenue guidance and potential acquisition, but tempered by the preliminary nature of the results and the risks associated with the acquisition.

Positives

• Sonendo's revenue is within the expected range for Q3 2024.
• The company has increased its full-year 2024 revenue guidance, indicating positive momentum.
• The company has a strong cash position with $17.3 million in cash, cash equivalents and short-term investments.
• The potential acquisition of Biolase assets could establish Sonendo as a leader in the endodontic space.
• The company has maintained a double-digit console backlog for the third straight quarter, indicating strong demand.

Negatives

• The financial results are preliminary and unaudited, and may be subject to adjustments.
• The company is still carrying a double-digit console backlog, which could indicate supply chain or production issues.
• The acquisition of Biolase assets is not guaranteed and is subject to bankruptcy court approval and other conditions.

Risks

• The preliminary financial results are subject to change after the completion of quarter-end procedures and review by the company's independent registered accounting firm.
• The acquisition of Biolase assets is not guaranteed and is subject to risks such as competing bids, bankruptcy court approval, and the ability to satisfy closing conditions.
• The integration of Biolase's assets, if acquired, could present challenges and may not result in the expected synergies or benefits.
• The company's future performance is subject to various risks and uncertainties, including market conditions, competition, and the ability to execute its strategic plans.
• The company may need to raise additional capital in the future, which could be affected by credit market conditions.

Future Outlook

Sonendo aims to finish the year strong and is focused on returning to growth, improving utilization, and expanding its customer base. The company is also pursuing the acquisition of certain assets of Biolase, Inc. to establish itself as a leader in the endodontic space.

Management Comments

• Bjarne Bergheim, President and CEO, stated that the company continued to effectively execute on the strategic reset initiated earlier in the year.
• Management is confident in the momentum moving into the fourth quarter to finish the year strong.
• Sonendo remains committed to returning to growth, delivering improved utilization and expanding its core customer base moving forward.
• The company believes that a combined company with Biolase presents a unique opportunity to establish Sonendo as the leader in the endodontic space.

Industry Context

The announcement comes as Sonendo seeks to strengthen its position in the dental technology market, particularly in the endodontic space. The potential acquisition of Biolase assets could significantly alter the competitive landscape.

Comparison to Industry Standards

• The document does not provide specific industry benchmarks for comparison.
• However, the revenue figures and growth guidance can be compared to other dental technology companies such as Dentsply Sirona, Align Technology, and Envista Holdings.
• The success of the Biolase acquisition will be compared to other acquisitions in the medical device space, such as the recent acquisition of medical device companies by larger players like Medtronic and Johnson & Johnson.
• The company's ability to reduce its backlog and improve its cash position will be compared to other companies in the medical device industry.

Stakeholder Impact

• Shareholders may react positively to the increased revenue guidance and potential acquisition.
• Employees may be impacted by the potential integration of Biolase's assets.
• Customers may benefit from the potential expansion of Sonendo's product offerings and services.
• Suppliers may see increased demand if the acquisition is successful.
• Creditors may be impacted by the company's financial performance and potential acquisition.

Next Steps

• Sonendo will continue its quarter-end closing procedures and review process.
• The company will provide further details on the potential acquisition of Biolase assets as the process unfolds.
• Sonendo will focus on executing its strategic plans to achieve growth and improve utilization.

Key Dates

Keywords

Sonendo, GentleWave System, Dental Technology, Endodontics, Revenue Guidance, Biolase, Acquisition, Financial Results, Stalking Horse Bid, Bankruptcy